-
Potential anti-epileptic drug market, Top 5 varieties account for over 80%!
Time of Update: 2022-01-24
In 2020, the sales of public hospitals in key cities will be 513 million yuan, with injections as the main dosage form (accounting for 70% of the share), Sanofi (65.
-
Human well-being medicine has exploded!
Time of Update: 2022-01-24
On January 13, 2022, Renfu Pharmaceutical announced that the company's second new class 1 traditional Chinese medicine drug was approved for clinical use .
-
In-depth inventory: In 2021, CDE will accept 1,439 applications for the registration of domestically produced Class 1 innovative drugs, and the number of traditional Chinese medicine applications reaches a new high!
Time of Update: 2022-01-24
Figure 9 Distribution of declarations by province in 2021 Data source: Yaozhi Data, Yaozhi Consulting Let us analyze in detail the registration acceptance and review of chemical drugs, traditional Chinese medicines, biological products, priority review and breakthrough therapy .
-
Medtronic to acquire Jianzhi cardiac ablation technology for the first time in 2022
Time of Update: 2022-01-24
Affera is a company that designs and develops cardiac mapping and navigation systems, as well as catheter-based cardiac ablation technologies, including differentiated focal pulsed field ablation solutions for the treatment of patients with cardiac arrhythmias, such as atrial fibrillation (AF) .
-
Current Situation and Prospects of Nano-vaccine Technology Development
Time of Update: 2022-01-24
The development of nanomedicine has provided multiple options for vaccine routes, including postoperative, intradermal/subcutaneous, intranasal, inhalation, and oral administration, for infectious diseases and cancer treatment .
Looking at vaccine nanotechnology currently under clinical development, mRNA-based nanovaccine holds great promise in cancer treatment and infectious disease prevention .
-
Express the development of small molecules to target and degrade RNA!
Time of Update: 2022-01-24
On January 11, 2022, Amgen and Arrakis Therapeutics announced a research collaboration to discover and develop RNA-degrading therapeutics for a range of difficult-to-drug targets across multiple therapeutic areas .
-
26 daily limit in 48 days, how is the "New Year's Eve Big Demon Stock"
Time of Update: 2022-01-24
Just look at the K-line chart of Jiu'an Medical to know how much our medical and medical sector needs a dose of chicken blood . As the most concerned "New Year's Eve monster" in the A-share market,
-
In the next step of centralized drug procurement, will the price drop be more than 50%?
Time of Update: 2022-01-24
Bidding is the process of making full use of the competition mechanism of the market, through which the bidder adopts a price reduction strategy to defeat the opponent in order to win the bid and achieve sales, so as to achieve the purpose of low-cost procurement .
-
Over $3 billion!
Time of Update: 2022-01-24
On January 10, Bristol-Myers Squibb (BMS) and Century Therapeutics (“Century”) announced a research collaboration and license agreement to jointly develop and commercialize iPSC-derived allogeneic cell therapies planned for the treatment of Hematological malignancies and solid tumors .
com/news-releases/news-release-details/century-therapeutics-and-bristol-myers-squibb-enter-strategichttps://investors.
com/news-releases/news-release-details/century-therapeutics-and-bristol-myers-squibb-enter-strategic
-
The market value has evaporated by nearly 400 billion, and the break has become the norm. Will the medical IPO be no longer in 2021?
Time of Update: 2022-01-24
Among the medical stocks IPOs in 2021, innovative pharmaceutical companies (15 deals), high-value consumables (15 deals) and biopharmaceuticals (including generic drugs and APIs, 14 deals) are the most popular tracks .
-
Roche invests $290 million in Freenome colorectal cancer screening program
Time of Update: 2022-01-24
S. die from colorectal cancer each year, and if the Roche-invested screening method can detect early and keep tumor cells localized, patients could have a 90 percent chance of survival .
-
The State Food and Drug Administration held a symposium on promoting the comprehensive revitalization of Northeast China
Time of Update: 2022-01-24
On the afternoon of January 13, the State Food and Drug Administration held a symposium on promoting the comprehensive revitalization of the Northeast, implementing the "14th Five-Year Plan for the C
-
Pharmaceutical companies are scrambling to focus on the development of innovative therapies, and a large number of patients will benefit in the future
Time of Update: 2022-01-21
According to data, domestic pharmaceutical companies have been actively deploying CAR-T cell therapy drugs in recent years .
-
Annual inventory of over 100 new drug transactions!
Time of Update: 2022-01-10
2021 is coming to an end, and China's biomedical industry will also end its one-year journey and open the next chapter . During this year, Chinese innovative pharmaceutical companies are also moving
-
Seven batches and eight rounds of national procurement communication meetings were held to adjust the forecasting rules in three aspects
Time of Update: 2022-01-10
Five batches and six rounds of national procurement of chemical medicines, the selection method adopted is based on the price from low to high, the relevant companies take turns to choose the area .
-
Bojian AD new drug price cuts by 50%
Time of Update: 2022-01-10
On December 20, Biogen announced that it would reduce the wholesale acquisition cost of the new Alzheimer’s disease drug Aduhelmd (100mg/ml specification) by approximately 50% from January 1, 2022 .
Biogen expects that 50,000 people will start using Aduhelmd treatment in 2022 .
-
milestone!
Time of Update: 2022-01-10
It is reported that the US government purchased 10 million courses of Pfizer's new crown oral drug Paxlovid at a price of US$5 billion .
-
Sina Pharmaceutical's annual inventory of domestically-made "Class 1/2" innovative drugs that entered the NDA for the first time in 2021
Time of Update: 2022-01-10
For the whole year of 2021, whether it is a category 1 innovative drug or a category 2 improved new drug, which domestically produced varieties will enter the NDA acceptance status for the first time?
-
What are the highlights of the global collection of clinical advances in RNAi drugs that are worth looking forward to?
Time of Update: 2022-01-10
Image source: Shengnuo Pharmaceutical Although RNAi therapy in oncology is in the early stage, and the representative drug STP705 is also in the phase II clinical stage, RNAi therapy can effectively inhibit the growth of advanced tumors in cancer treatment, with relatively low cost and high specificity.
-
New domestic anti-cancer drugs embark on a virtuous circle, and many pharmaceutical companies recently announced new breakthroughs
Time of Update: 2022-01-10
For example, Zhejiang Medicine issued an announcement recently that the company's subsidiary Xinma Biology's new anti-cancer drug, a recombinant humanized anti-CD70 monoclonal antibody-AS269 conjugate for injection (code: ARX305), has been accepted for registration of clinical trials .
Increasing the innovative research and development of domestic anti-tumor drugs to provide more cancer patients with new drug treatment options.